Citation Impact
Citing Papers
Treatment for Acute Myelogenous Leukemia by Low-Dose, Total-Body, Irradiation-Based Conditioning and Hematopoietic Cell Transplantation From Related and Unrelated Donors
2005
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
2011 Standout
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease
2007
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
2002
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
2017
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients
2016 Standout
HLA Match Likelihoods for Hematopoietic Stem-Cell Grafts in the U.S. Registry
2014 Standout
Approaches to transplantation tolerance in humans
2004
Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective
2009 Standout
Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation
2001
Prospective evaluation of antiemetic outcome following high-dose chemotherapy with hematopoietic stem cell support
2001
Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning
2003
Thrombotic Microangiopathy after Allogeneic Blood and Marrow Transplantation Is Associated with Dose-Intensive Myeloablative Conditioning Regimens, Unrelated Donor, and Methylprednisolone T-Cell Depletion
2004
The Transplantation of Hematopoietic Stem Cells After Non-Myeloablative Conditioning: A Cellular Therapeutic Approach to Hematologic and Genetic Diseases
2003
Haematopoietic cell transplantation as immunotherapy
2001 Nature
Transplantation-associated thrombotic microangiopathy after steroid pulse therapy for polyserositis related to graft-versus-host disease
2010 StandoutNobel
Allogeneic Offspring Produced by Male Germ Line Stem Cell Transplantation into Infertile Mouse Testis1
2003 StandoutNobel
Vascular disorders of the liver # †
2008 Standout
Review of “Minitransplantation”: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
2003
Chronic graft-versus-host disease
2003 Standout
Cancer-associated cachexia
2018 Standout
Cancer genes and the pathways they control
2004 Standout
Antibody therapy of cancer
2012 Standout
Development and validation of a scale to measure symptoms of chronic graft-versus-host disease
2002
Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement
2004
Graft-versus-host disease
2009 Standout
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Sirolimus, Tacrolimus, and Low-Dose Methotrexate as Graft-versus-Host Disease Prophylaxis in Related and Unrelated Donor Reduced-Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation
2008
Elderly age and prior autologous transplantation have a deleterious effect on survival following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results from the Spanish multicenter prospective trial
2004
Chemotherapy-Induced Nausea and Vomiting
2008 Standout
Biology and management of relapsed acute myeloid leukaemia
2005
Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation
2010 Standout
Chronic Myelogenous Leukemia
2002
Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?
2007 Standout
Hematopoietic Stem-Cell Transplantation
2006 Standout
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
2013 Standout
Protective Conditioning for Acute Graft-versus-Host Disease
2005
Idarucizumab for Dabigatran Reversal
2015 Standout
Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age>55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning
2004
Defining the Intensity of Conditioning Regimens: Working Definitions
2009 Standout
Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation
2006
Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation
2004
Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab
2004
Infectious risks and outcomes after stem cell transplantation: are nonmyeloablative transplants changing the picture?
2002
Posttransplantation Thrombotic Thrombocytopenic Purpura: A Single-Center Experience and a Contemporary Review
2003
Do minitransplants have minicosts? A cost comparison between myeloablative and nonmyeloablative allogeneic stem cell transplant in patients with acute myeloid leukemia
2005
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
2019 Standout
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
2015 Standout
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
2013 StandoutNobel
Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies
2008
The side effects of platinum-based chemotherapy drugs: a review for chemists
2018 Standout
Allogeneic Stem-Cell Transplantation Using a Reduced-Intensity Conditioning Regimen Has the Capacity to Produce Durable Remissions and Long-Term Disease-Free Survival in Patients With High-Risk Acute Myeloid Leukemia and Myelodysplasia
2005
Sexually Transmitted Infections Treatment Guidelines, 2021
2021 Standout
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS
2004
Acute Myeloid Leukemia
2015 Standout
Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities
2004
Timing and duration of 5-HT3 receptor antagonist therapy for the prophylaxis of radiotherapy-induced nausea and vomiting: a systematic review of randomized and non-randomized studies
2012
Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation
2003
ICRP PUBLICATION 118: ICRP Statement on Tissue Reactions and Early and Late Effects of Radiation in Normal Tissues and Organs — Threshold Doses for Tissue Reactions in a Radiation Protection Context
2012 Standout
Estrogen Metabolite 2-Methoxyestradiol Induces Apoptosis and Inhibits Cell Proliferation and Collagen Production in Rat and Human Leiomyoma Cells: A Potential Medicinal Treatment for Uterine Fibroids
2006 Standout
Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
2011 Standout
Medical Management of the Acute Radiation Syndrome: Recommendations of the Strategic National Stockpile Radiation Working Group
2004
Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years
2003
Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies
2001
Fludarabine in the treatment of chronic lymphocytic leukemia: a review
2009
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
2016 Standout
Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells
2003
Conditioning regimens for hematopoietic cell transplantation: one size does not fit all
2014
Next Generation of Immunotherapy for Melanoma
2008
Cancer treatment and survivorship statistics, 2016
2016 Standout
Cancer treatment and survivorship statistics, 2019
2019 Standout
Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning
2003
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT
2005 Standout
HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies
2003
Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors
2004
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation
2002
2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host
2013 Standout
Guidelines for Treatment of Candidiasis
2004 Standout
Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects
2011
Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy
2003
HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen
2003
Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders
2002
The Impact of a Reported Penicillin Allergy on Surgical Site Infection Risk
2017
Preventing and Managing Toxicities of High-Dose Methotrexate
2016 Standout
Works of J Bruton being referenced
Granisetron (Kytril) plus dexamethasone for antiemetic control in bone marrow transplant patients receiving highly emetogenic chemotherapy with or without total body irradiation
2000
Toxicity of single daily dose gentamicin in stem cell transplantation
1999
Antiemetic efficacy of granisetron plus dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation
1999
Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
2001
Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
2001
Recombinant Interleukin‐2
1994